Results

1–8 of 8 results for VEGF D

COAST: A Phase 3 Study of Intravitreal Sozinibercept Combined With Aflibercept in Participants With Neovascular Age-Related Macular Degeneration
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2025
LEAVO Trial - Comparison of Anti-VEGF drugs for Macular Edema Secondary to CRVO- Dr. Philip Hykin
Keyvan Koushan, MD, FRCSC
Member Podcasts
2020
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Updates from the Field
2019
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Annual Meeting Talks
2019
Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration Across Key Clinical Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2018
Genetic Variants Associated With Anti-VEGF Drug Response in Neovascular AMD Patients in the View Trial
Nancy M. Holekamp, MD, FASRS
Updates from the Field
2016
Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration
David A. Eichenbaum, MD, FASRS
Updates from the Field
2018
The Evidence Behind Extended Anti-VEGF Dosing in Neovascular Age-Related Macular Degeneration: A 6 Trial Cross-Comparison
Theodore Leng, MD, MS, FASRS
Updates from the Field
2019